Wednesday, 4 November 2026LatestVideosAboutContact
Latest
AMD rides data center riches to ‘largest and most profitable’ quarter in history‘I'll be the fielding coach’: Ex-cricketer mocks India as BCCI invites applicationsMan United stun Roma with comeback win to ease pressure on Michael CarrickAll the news about The Legend of Zelda: Ocarina of Time remakeChampions League: Manchester United stage dramatic comeback, PSG thrash Villarreal; Barcelona and Bayern emerge victoriousStudy maps Nelore cattle microbiota to reduce methane emissionsMukesh Ambani’s Jio holds talks with Comcast, Charter for US broadband technology dealRanbir Kapoor's 'Ramayana' Gets A Starry Mumbai Screening Ahead Of Release; Alia Bhatt, Neetu Kapoor AttendUS midterm exit polls: Two-thirds of voters blame Trump for high pricesThe biggest modding site in PC gaming is taking a stance on AINorth Atlantic's 'cold blob' may contain climate nuanceHow the nasal microbiome can help potentially harmful bacteria thrive
ScienceUpdated 1 hr ago

Semiautomated platform delivers consistent batches of extracellular vesicles for potential regenerative therapies

Image: Phys.org

A study led by researchers from the Germans Trias i Pujol Research Institute (IGTP) and the Blood and Tissue Bank (BST) has developed and validated a manufacturing platform for extracellular vesicles that meets pharmaceutical quality requirements, marking a key step toward their clinical application.

Continue reading on Phys.org

Hello Headlines links you to the original publisher for the full story.

Read full story

More in Science

See all